SEEKYO Therapeutics

Seekyo Therapeutics, founded in 2018 and based in Paris, is pioneering a new paradigm in oncology with its Tumor Activated Therapy™ platform. This approach targets functional proteins selectively produced within the tumor microenvironment, enabling localized activation of therapeutic agents to overcome tumor heterogeneity and reduce systemic toxicity. The company's lead program, SKY01, has demonstrated efficacy and safety in animal models across multiple difficult-to-treat solid tumors, positioning Seekyo to address a significant unmet need in oncology. It operates as a private, preclinical-stage biotech seeking partnerships to advance its internal pipeline and platform.

SKY™ platform enabling Tumor Activated Therapy™; uses targeting units that bind to functional proteins in the tumor microenvironment (TME), connected via cleavable linkers to therapeutic payloads (cytotoxics, immuno-stimulants). Activation is triggered by TME-specific biochemistry, aiming for selective tumor destruction independent of cancer cell surface markers.

Seeks to compete in the targeted oncology space against antibody-drug conjugates (ADCs), other prodrug platforms, and tumor-microenvironment targeting therapies. Its key proposed differentiator is activation via TME functional proteins, independent of cancer cell surface markers, to address heterogeneity.